SCHEMBL12879138

SCHEMBL12879138

COCCOC1[C@@H](O)[C@@H](CO)O[C@H]1n1cnc(C(N)=O)n1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 4/20 0.68
▸ SMN1; SMN2 Q16637 3/20 0.68
▸ ADORA1 P30542 3/20 0.68
▸ ALDH1A1 P00352 3/20 0.68
▸ TSHR P16473 2/20 0.68
▸ THPO P40225 2/20 0.68
▸ PMP22 Q01453 2/20 0.68
▸ GLA P06280 1/20 0.68
▸ EIF4E P06730 1/20 0.68
▸ CYP3A4 P08684 1/20 0.68
▸ TOP1 P11387 1/20 0.68
▸ PNP P00491 3/20 0.53
▸ KDM4E B2RXH2 2/20 0.42
▸ HTT P42858 2/20 0.42
▸ BLM P54132 2/20 0.42
▸ TP53 P04637 2/20 0.42
▸ TDP1 Q9NUW8 1/20 0.42
▸ GAA P10253 1/20 0.42
▸ MAPT P10636 1/20 0.42
▸ HTR2C P28335 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12879143 1.00 LMNA (0.68) LMNASMN1; SMN2ADORA1ALDH1A1TSHR
SCHEMBL16116621 0.90 LMNA (0.54) LMNASMN1; SMN2ADORA1ALDH1A1TSHR
SCHEMBL15031296 0.89 LMNA (0.74) LMNASMN1; SMN2ADORA1ALDH1A1TSHR
SCHEMBL12879139 0.87 LMNA (0.50) LMNASMN1; SMN2ADORA1ALDH1A1TSHR
SCHEMBL12879135 0.87 LMNA (0.50) LMNASMN1; SMN2ADORA1ALDH1A1TSHR
SCHEMBL5897238 0.84 LMNA (0.69) LMNASMN1; SMN2ADORA1ALDH1A1TSHR
Ribavirin SCHEMBL28329293 0.83 LMNA (0.97) LMNASMN1; SMN2ADORA1ALDH1A1TSHR
SCHEMBL14546644 0.82 LMNA (0.74) LMNASMN1; SMN2ADORA1ALDH1A1TSHR
Ribavirin SCHEMBL28099209 0.82 LMNA (0.95) LMNASMN1; SMN2ADORA1ALDH1A1TSHR
Ribavirin SCHEMBL3727 0.81 LMNA (1.00) LMNASMN1; SMN2ADORA1ALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8466276-B2 Oligomer conjugates of heteropentacyclic nucleosides NEKTAR THERAPEUTICS (US) 2013-06-18 — — US disclosed
US-20110039797-A1 Oligomer Conjugates of Heteropentacyclic Nucleosides Nektar Therapetics (US) 2011-02-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110039797-A1 Oligomer Conjugates of Heteropentacyclic Nucleosides SLC29A2, SLC29A1, GNE LMNA 3873/4885SMN1; SMN2 2799/4885ADORA1 93/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback